What was the median PFS with pluvicto alone in patients with oligometastatic castration sensitive prostate cancer in the BULLSEYE trial?
What was the complete response rate at 1 year in a recent retrospective study comparing 4 Gy in 2 fractions and 8 Gy in 2 fractions for indolent lymphoma?
In patients receiving enzalutamide for mCRPC, what proportion of radiographic progression events happen without a significant rise in the PSA?
Answers
25 months. The rate of complete biochemical response was 24%, and 83% of patients had at least a 50% drop in their PSA. Median time to next systemic therapy was 26 months.
81% v 57%. Local progression was also significantly lower with 8 Gy (7% v 26%).
50-60% when using the PCWG criteria for PSA progression, and 22-25% had no rise in the PSA at all when there was radiographic progression. | QuadShot News
What was the complete response rate at 1 year in a recent retrospective study comparing 4 Gy in 2 fractions and 8 Gy in 2 fractions for indolent lymphoma?
In patients receiving enzalutamide for mCRPC, what proportion of radiographic progression events happen without a significant rise in the PSA?
Answers
25 months. The rate of complete biochemical response was 24%, and 83% of patients had at least a 50% drop in their PSA. Median time to next systemic therapy was 26 months.
81% v 57%. Local progression was also significantly lower with 8 Gy (7% v 26%).
50-60% when using the PCWG criteria for PSA progression, and 22-25% had no rise in the PSA at all when there was radiographic progression. | QuadShot News